Biopharma news, November 14, 2026
The most important drug and company news of November 14, 2026, ranked, each linked to its Gosset profiles.
Pivotal readout
Henlius Achieves Full Reimbursement Coverage
China's 2026 national reimbursement list includes all five approved indications for Henlius's serplulimab and adds first-line reimbursement for fuviciclib in HR-positive, HER2-negative advanced breast cancer. All eight Henlius products marketed in China are now included in the national reimbursement list, which takes effect on January 1, 2027. The company reports that long-term follow-up from a phase 3 fuviciclib study showed a 33% lower risk of death versus placebo.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
M&A
Tong Ren Tang Acquisition
Beijing Tong Ren Tang plans to buy its parent group's 60% stake in Tianjin Tong Ren Tang for RMB 2.4438 billion in cash. The implied RMB 4.073 billion equity valuation values Livzon's retained 40% stake at about RMB 1.629 billion, representing an estimated unrealized gain of RMB 813 million over its reported carrying value. The acquisition is intended to combine retail and hospital channels and address potential competition within the Tong Ren Tang group.
Source types: News article. Sources are available to Gosset users. Log in to see them.